<h1>Regulatory approvals expand CDMO product mix while EU dossier commercialization and patent protection support global manufacturing growth.</h1> Regulatory approvals anchor the company's CDMO expansion: cumulative national drug regulator approvals including new grants, a patent for an extended release combination formulation using tablet in tablet technology, an EU dossier approval and a Swiss dossier filing with EU commercialization scheduled per the company's timetable; these events coincide with an upfront contractual consideration and a reported strong liquidity position. The release also presents adjusted EBITDA and adjusted PAT definitions and reports quarter on quarter margin and profitability improvements, identifying the CDMO segment as the principal revenue and EBITDA contributor and noting continued management efforts to reduce losses in trade generics and API segments.